April 8, 2010 -
PRLog -- This report examines trends in the $36 billion dyslipidemia market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals. Cholesterol (LDL and HDL) and triglycerides need to be controlled in individuals at risk of developing new or worsening cardiovascular disease (primary and secondary prevention). Antidyslipidemics on the market include statins, ezetimibe, fibrates, niacin products, bile acid sequestrants, and prescription omega-3 products. Many clinical trials over the past 30 years or so have shown that treatment with these drugs substantially reduces cardiovascular risk. The report reviews current approaches to treatment, drugs on the market, marketing strategies, lessons learnt from landmark clinical trials, biomarkers, surrogates of atherosclerosis for drug development, and over 150 products in commercial development. It also derives market forecasts (for the period 2008 to 2012) and assesses market potential.
For more information please visit:
http://www.aarkstore.com/reports/Dyslipidemia-Opportuniti...PH.NO. 919272852585
# # #
Aarkstore Enterprise specializes in providing business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
